article = {IJCST-2021-1-101}
title = {Optimal Upfront CLL Treatment during the COVID-19 Pandemic}
journal = {International Journal of Cancer Science and Therapy}
year = {2021}
issn = {}
doi = {http://dx.doi.org/10.31487/j.IJCST.2021.01.01}
url = {https://www.sciencerepository.org/optimal-upfront-cll-treatment-during-the-covid-19-pandemic_IJCST-2021-1-101 
author = {Ezzat Elhassadi,}
keywords = {COVID-19 & SARS CoV-2, pandemic, chronic lymphocytic leukemia, Ibrutinib}
abstract ={The coronavirus disease 2019 (COVID-19) pandemic has challenged our healthcare systems and threatened individuals worldwide, particularly the most vulnerable elderly and those with medical comorbidities. The emergence of the new virus variant with its increased infectivity threats requires a quick response before the availability of evidence on managing patients with chronic lymphocytic leukemia (CLL) in this pandemic. Accordingly, this document prepared to provide informed opinions based on available evidence on how CLL patients were treated during the pandemic period.}